Beijing Tiantan Biological Products Co., Ltd.

Shanghai Stock Exchange 600161.SS

Beijing Tiantan Biological Products Co., Ltd. Receivables for the year ending December 31, 2023: USD 0.00

Beijing Tiantan Biological Products Co., Ltd. Receivables is USD 0.00 for the year ending December 31, 2023, a -100.00% change year over year. Receivables are the amounts owed to the company by customers for goods sold or services rendered.

Beijing Tiantan Biological Products Co., Ltd. Receivables for the year ending December 31, 2022 was USD 174.03 M, a 7.64% change year over year.
Beijing Tiantan Biological Products Co., Ltd. Receivables for the year ending December 31, 2021 was USD 161.67 M, a 51.72% change year over year.
Beijing Tiantan Biological Products Co., Ltd. Receivables for the year ending December 31, 2020 was USD 106.56 M, a 16.59% change year over year.
Beijing Tiantan Biological Products Co., Ltd. Receivables for the year ending December 31, 2019 was USD 91.40 M, a 43.65% change year over year.

Key data

Date	Receivables	Inventory	Goodwill	Total Assets

Shanghai Stock Exchange: 600161.SS

Beijing Tiantan Biological Products Co., Ltd.

CEO	Mr. Dao Xing Fu
IPO Date	June 16, 1998
Location	China
Headquarters	No. 2 Courtyard
Employees	4,858
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Beijing Tiantan Biological Products Co., Ltd. engages in the research and development, manufacture, sale, and consulting of blood products in China. Its products include blood intravenous injection immunoglobulin; blood human albumin; blood system intravenous injection; hepatitis B, freeze-dried hepatitis B, and tetanus human immunoglobulin; human immunoglobulin; and other blood products. The company was incorporated in 1998 and is headquartered in Beijing, China. Beijing Tiantan Biological Products Co., Ltd. operates as a subsidiary of China National Biotec Group Company Limited.

Key trends

Past 5 years